<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Bioenergetic Vulnerability Threshold Theory - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Theory Details for theory-6</h1>

        <div class="section">
            <h2>Theory (General Information)</h2>
            <div class="info-section">
                <p><strong>ID:</strong> theory-6</p>
                <p><strong>Name:</strong> Bioenergetic Vulnerability Threshold Theory</p>
                <p><strong>Type:</strong> general</p>
                <p><strong>Theory Query:</strong> Build a theory of which cell types are most susceptible and most resilient in Alzheimer's disease and the mechanisms explaining these differences, based on the following results.</p>
                <p><strong>Description:</strong> Selective neuronal vulnerability in Alzheimer's disease is fundamentally determined by the mismatch between a neuron's intrinsic metabolic/energetic demands and its capacity to maintain energy production through mitochondrial oxidative phosphorylation. Neurons with high baseline metabolic activity (large projection neurons, neurons in high-activity regions like posterior cingulate cortex) that undergo AD-related downregulation of nuclear-encoded mitochondrial genes fall below a critical bioenergetic threshold, leading to synaptic dysfunction, loss of calcium homeostasis, and ultimately cell death. This vulnerability is anatomically patterned by regional metabolic demands and cellular properties such as projection length, dendritic arbor complexity, and synaptic density.</p>
                <p><strong>Knowledge Cutoff Year:</strong> 2029</p>
                <p><strong>Knowledge Cutoff Month:</strong> 12</p>
                <p><strong>Base Model:</strong> claude-sonnet-4-5-20250929</p>
            </div>
        </div>
        </div>

        <div class="section">
            <h2>Theory (Statement/Laws)</h2>

            <h3>Theory Statements/Laws</h3>
            <hr/>
            <h3>Statement 0: Regional Metabolic Demand-Vulnerability Gradient</h3>
            <p><strong>Statement:</strong> Brain regions and neuronal populations ranked by baseline metabolic activity (measured by PET glucose metabolism) show a proportional ranking of mitochondrial gene downregulation in AD and neuronal vulnerability. High-demand regions (posterior cingulate cortex, middle temporal gyrus, hippocampus CA1) show 61-70% of mitochondrial ETC genes underexpressed, while low-demand regions (visual cortex, superior frontal gyrus) show 5-16% underexpression, directly correlating with neuronal loss patterns.</p>
            <p><strong>Domain/Scope:</strong> Applies to cortical and allocortical brain regions in human AD assessed by transcriptomic profiling of laser-captured neurons and validated by PET imaging studies of regional glucose metabolism, across Braak stages V-VI (late-stage AD with established pathology).</p>
            <h4>Special Cases</h4>
            <ol>
                <li>Requires consideration of regional differences in neuron type composition</li>
                <li>Primary motor cortex represents an exception with relatively preserved function despite moderate activity levels</li>
                <li>Very early disease stages may not yet show the full gradient pattern</li>
            </ol>
            <h4>Supporting Evidence for this Law</h4>
<ol>
    <li>PCC layer III pyramidal neurons show 70% of assessed nuclear-encoded mitochondrial ETC genes significantly underexpressed with fold-reductions of 2.8-3.8 across complexes I-V, and PCC is the region with earliest PET hypometabolism in preclinical AD. <a href="../results/extraction-result-143.html#e143.0" class="evidence-link">[e143.0]</a> </li>
    <li>MTG layer III pyramidal neurons show 65% of mitochondrial ETC genes underexpressed with similar fold-reduction magnitudes (2.3-3.3), ranking second in vulnerability. <a href="../results/extraction-result-143.html#e143.1" class="evidence-link">[e143.1]</a> </li>
    <li>Hippocampal CA1 pyramidal neurons show 61% of mitochondrial ETC genes underexpressed, and CA1 is classically vulnerable with early NFT formation and marked cell loss. <a href="../results/extraction-result-143.html#e143.2" class="evidence-link">[e143.2]</a> <a href="../results/extraction-result-23.html#e23.0" class="evidence-link">[e23.0]</a> </li>
    <li>Entorhinal cortex layer II stellate neurons show only 23% of mitochondrial ETC genes underexpressed despite being anatomically vulnerable, suggesting partial metabolic resilience in this population. <a href="../results/extraction-result-143.html#e143.3" class="evidence-link">[e143.3]</a> </li>
    <li>Primary visual cortex layer III pyramidal neurons show only 16% of mitochondrial ETC genes underexpressed with smaller fold-change magnitudes, and visual cortex is relatively spared in AD. <a href="../results/extraction-result-143.html#e143.4" class="evidence-link">[e143.4]</a> </li>
    <li>Superior frontal gyrus neurons show minimal (5%) mitochondrial ETC gene underexpression and the region is associated with normal aging effects rather than AD-specific changes. <a href="../results/extraction-result-143.html#e143.5" class="evidence-link">[e143.5]</a> </li>
    <li>Cerebellar neurons show the fewest age- or AD-related transcriptomic changes and lowest oxidative DNA damage accumulation among brain regions, consistent with low metabolic rate. <a href="../results/extraction-result-23.html#e23.8" class="evidence-link">[e23.8]</a> </li>
    <li>Protein-level validation in PCC shows reductions to 41.9-72.4% of control levels for ETC complex subunits, confirming transcriptional changes translate to functional protein deficits. <a href="../results/extraction-result-143.html#e143.0" class="evidence-link">[e143.0]</a> </li>
</ol>            <h4>Self-Evaluation of Law Novelty (produced by the generation model)</h4>
            <p><strong>Likely Classification:</strong> <span style="color: orange; font-weight: bold;">somewhat-related-to-existing</span></p>
        <p><strong>Explanation:</strong> The systematic quantitative correlation across multiple regions with cell-type-specific transcriptomics represents a novel integration of existing concepts with high-resolution molecular data.</p>            <p><strong>What Already Exists:</strong> Regional vulnerability patterns in AD are well-established, and mitochondrial dysfunction has been implicated in AD pathogenesis. PET studies show regional hypometabolism patterns.</p>            <p><strong>What is Novel:</strong> This statement provides a quantitative ranking of mitochondrial ETC gene underexpression (5% to 70%) across brain regions that directly correlates with both PET metabolic patterns and neuroanatomical vulnerability, establishing a dose-response relationship between baseline metabolic demand and transcriptional bioenergetic failure.</p>
        <p><strong>References:</strong> <ul>
    <li>Mosconi et al. (2008) Hippocampal hypometabolism predicts cognitive decline from normal aging [PET metabolic patterns in preclinical AD]</li>
    <li>Swerdlow & Khan (2004) A mitochondrial cascade hypothesis for sporadic Alzheimer's disease [Mitochondrial cascade hypothesis]</li>
    <li>Liang et al. (2008) Alzheimer's disease is associated with reduced expression of energy metabolism genes in posterior cingulate neurons [Regional mitochondrial gene differences, source paper for this theory]</li>
</ul>
            <h4>External Evaluations of this Law</h4>
            <p><strong>Predictive Accuracy Evaluation:</strong> <span class="empty-note">Not available.</span></p>
            <p><strong>Novelty Evaluation:</strong> <span class="empty-note">Not available (available only for a randomly selected subset of 100 laws, due to cost).</span></p>
            <hr/>
            <h3>Statement 1: Complex I Dysregulation in Vulnerable Subtypes</h3>
            <p><strong>Statement:</strong> Within anatomically vulnerable regions, specific neuronal subtypes showing selective loss exhibit subtype-specific upregulation of mitochondrial complex I genes (MT-ND1, MT-ND3, MT-ND4) coupled with perturbations in NAD+/NADH metabolism and coenzyme Q10 handling, representing a maladaptive bioenergetic response that paradoxically increases vulnerability through altered electron transport chain activity.</p>
            <p><strong>Domain/Scope:</strong> Applies to specific vulnerable excitatory neuron sub-clusters (particularly layer II-VI excitatory neurons) in entorhinal cortex in human AD, identified by single-nucleus RNA-seq with cellular resolution.</p>
            <h4>Special Cases</h4>
            <ol>
                <li>Effect is subtype-specific and not seen in all neurons within vulnerable regions</li>
                <li>Other vulnerable subtypes may show different metabolic perturbations (e.g., ganglioside metabolism in interneurons)</li>
                <li>Temporal dynamics of complex I changes across disease stages are not fully characterized</li>
            </ol>
            <h4>Supporting Evidence for this Law</h4>
<ol>
    <li>Excitatory neuron sub-cluster n2 (layers II-VI, selectively vulnerable) shows subtype-specific upregulation of mitochondrial complex I genes MT-ND1, MT-ND3, MT-ND4 in AD vs control. <a href="../results/extraction-result-24.html#e24.0" class="evidence-link">[e24.0]</a> </li>
    <li>n2 neurons show perturbations in NAD/coenzyme Q10-centered metabolism detected by metabolite-centric perturb-Met analysis, linking complex I gene changes to functional metabolic alterations. <a href="../results/extraction-result-24.html#e24.0" class="evidence-link">[e24.0]</a> </li>
    <li>Complex I up-regulation is unique to n2 among examined neuronal sub-clusters; n3 shows little change, demonstrating subtype-specificity. <a href="../results/extraction-result-24.html#e24.0" class="evidence-link">[e24.0]</a> </li>
    <li>Literature supports that partial complex I inhibition can be protective in models, suggesting that altered complex I activity in vulnerable neurons may be maladaptive. <a href="../results/extraction-result-24.html#e24.0" class="evidence-link">[e24.0]</a> </li>
    <li>Bulk region-level analysis shows overall mitochondrial gene downregulation, but single-cell resolution reveals this vulnerable subtype shows paradoxical upregulation missed by averaging. <a href="../results/extraction-result-24.html#e24.0" class="evidence-link">[e24.0]</a> </li>
</ol>            <h4>Self-Evaluation of Law Novelty (produced by the generation model)</h4>
            <p><strong>Likely Classification:</strong> <span style="color: orange; font-weight: bold;">somewhat-related-to-existing</span></p>
        <p><strong>Explanation:</strong> The paradoxical upregulation and subtype-specificity represent a novel finding that refines understanding of mitochondrial dysfunction beyond simple 'deficiency' models.</p>            <p><strong>What Already Exists:</strong> Mitochondrial complex I dysfunction has been reported in AD, typically described as reduced activity or expression.</p>            <p><strong>What is Novel:</strong> This statement identifies subtype-specific upregulation (not downregulation) of complex I components in vulnerable neurons, representing a paradoxical finding that suggests maladaptive compensation rather than simple failure, and links this to NAD metabolism perturbations at single-cell resolution.</p>
        <p><strong>References:</strong> <ul>
    <li>Parker et al. (1994) Reduced platelet cytochrome c oxidase activity in Alzheimer's disease [Complex I-IV dysfunction in AD]</li>
    <li>Manczak et al. (2004) Mitochondria are a direct site of Aβ accumulation in Alzheimer's disease neurons [Mitochondrial Aβ effects]</li>
    <li>Yin et al. (2021) Identifying neuron subtype-specific metabolic network changes in single cell transcriptomics of Alzheimer's Disease using perturb-Met [Source paper for this finding, methodology for detecting subtype-specific metabolic changes]</li>
</ul>
            <h4>External Evaluations of this Law</h4>
            <p><strong>Predictive Accuracy Evaluation:</strong> <span class="empty-note">Not available.</span></p>
            <p><strong>Novelty Evaluation:</strong> <span class="empty-note">Not available (available only for a randomly selected subset of 100 laws, due to cost).</span></p>
            <hr/>
            <h3>Statement 2: Projection Length and Arbor Complexity Vulnerability</h3>
            <p><strong>Statement:</strong> Neurons with long-range axonal projections and extensive dendritic arbors (large pyramidal association neurons, basal forebrain cholinergic neurons, entorhinal layer II perforant pathway neurons) are selectively vulnerable due to high metabolic costs of maintaining axonal transport, synaptic vesicle cycling at numerous distant terminals, and large membrane surface area, creating high baseline energy demands that cannot be sustained when mitochondrial function declines.</p>
            <p><strong>Domain/Scope:</strong> Applies to projection neuron populations across cortical and subcortical regions in human AD and animal models, particularly large pyramidal neurons in association cortices, entorhinal cortex layer II, hippocampal CA1, and basal forebrain cholinergic neurons.</p>
            <h4>Special Cases</h4>
            <ol>
                <li>Does not explain vulnerability of some interneuron subtypes with relatively local projections</li>
                <li>Primary motor neurons with long projections show relative resilience, suggesting additional protective factors</li>
                <li>Developmental stage and age at disease onset may affect vulnerability of projection neurons</li>
            </ol>
            <h4>Supporting Evidence for this Law</h4>
<ol>
    <li>Large pyramidal association neurons with long-range projections in entorhinal layer II, subiculum, and association cortex are repeatedly identified as highly vulnerable class, among the first lost in early disease. <a href="../results/extraction-result-23.html#e23.5" class="evidence-link">[e23.5]</a> </li>
    <li>Entorhinal layer II neurons providing major perforant pathway input to hippocampus show profound loss (60% reduction in CDR 0.5, 87% in CDR 3) very early in disease. <a href="../results/extraction-result-141.html#e141.0" class="evidence-link">[e141.0]</a> </li>
    <li>CA1 pyramidal neurons with extensive projections show marked transcriptional downregulation of energy metabolism, synaptic, and cytoskeletal genes, and are highly vulnerable with early NFT accumulation. <a href="../results/extraction-result-23.html#e23.0" class="evidence-link">[e23.0]</a> <a href="../results/extraction-result-142.html#e142.1" class="evidence-link">[e142.1]</a> </li>
    <li>Nucleus basalis cholinergic neurons with widespread cortical projections show selective vulnerability with downregulation of neurotrophin receptors, synaptic proteins, and energy metabolism genes. <a href="../results/extraction-result-23.html#e23.4" class="evidence-link">[e23.4]</a> </li>
    <li>Basal forebrain cholinergic neurons derived from AD patient iPSCs show increased susceptibility to cell death and excitotoxic stress with elevated intracellular Ca2+. <a href="../results/extraction-result-21.html#e21.2" class="evidence-link">[e21.2]</a> </li>
    <li>Layer III cortical pyramidal neurons (corticocortical projection neurons) across multiple regions show region-dependent vulnerability with downregulation of synaptic and cytoskeletal genes. <a href="../results/extraction-result-142.html#e142.2" class="evidence-link">[e142.2]</a> </li>
    <li>Proposed mechanisms explicitly include high energy/mitochondrial demand, long axons increasing transport burden, and large surface area exposure. <a href="../results/extraction-result-23.html#e23.5" class="evidence-link">[e23.5]</a> <a href="../results/extraction-result-23.html#e23.2" class="evidence-link">[e23.2]</a> </li>
</ol>            <h4>Self-Evaluation of Law Novelty (produced by the generation model)</h4>
            <p><strong>Likely Classification:</strong> closely-related-to-existing</p>
        <p><strong>Explanation:</strong> The explicit mechanistic linking of anatomical properties to transcriptomic bioenergetic profiles represents an integration of classical observations with modern molecular data.</p>            <p><strong>What Already Exists:</strong> Selective vulnerability of large projection neurons in AD is well-established in classical neuropathology, and metabolic burden of axonal transport is recognized.</p>            <p><strong>What is Novel:</strong> This statement explicitly quantifies the relationship between projection properties (length, arbor complexity) and metabolic gene downregulation with cell-type-specific transcriptomic data, mechanistically linking neuroanatomical properties to molecular bioenergetic failure.</p>
        <p><strong>References:</strong> <ul>
    <li>Braak & Braak (1991) Neuropathological stageing of Alzheimer-related changes [Classical neuropathology of vulnerable populations]</li>
    <li>Morrison & Hof (1997) Life and death of neurons in the aging brain [Projection neuron vulnerability]</li>
    <li>Stokin et al. (2005) Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease [Axonal transport deficits in AD]</li>
</ul>
            <h4>External Evaluations of this Law</h4>
            <p><strong>Predictive Accuracy Evaluation:</strong> <span class="empty-note">Not available.</span></p>
            <p><strong>Novelty Evaluation:</strong> <span class="empty-note">Not available (available only for a randomly selected subset of 100 laws, due to cost).</span></p>
            <hr/>
            <h3>Statement 3: Mitochondrial Protein Import Failure</h3>
            <p><strong>Statement:</strong> Downregulation of mitochondrial translocases (TIMM/TOMM complex components) in vulnerable neurons impairs import of nuclear-encoded mitochondrial proteins, creating a bottleneck that prevents assembly of functional electron transport chain complexes even when some ETC subunit transcripts are present, thereby amplifying bioenergetic failure.</p>
            <p><strong>Domain/Scope:</strong> Applies to vulnerable neuronal populations showing mitochondrial gene downregulation across cortical and hippocampal regions in human AD, particularly PCC, MTG, and CA1 neurons.</p>
            <h4>Special Cases</h4>
            <ol>
                <li>Effect magnitude varies by region (PCC and MTG show greater TIMM/TOMM underexpression than other regions)</li>
                <li>Mitochondrial-encoded ETC subunits may show different patterns than nuclear-encoded subunits</li>
                <li>Compensatory mechanisms may partially ameliorate import deficiency in some neurons</li>
            </ol>
            <h4>Supporting Evidence for this Law</h4>
<ol>
    <li>PCC neurons show TIMM underexpression in 27% of assessed subunits and TOMM underexpression in 50% of subunits, with fold-reductions similar to ETC genes. <a href="../results/extraction-result-143.html#e143.0" class="evidence-link">[e143.0]</a> </li>
    <li>MTG neurons show TIMM underexpression in 27% and TOMM underexpression in 83% of assessed subunits, representing substantial import machinery impairment. <a href="../results/extraction-result-143.html#e143.1" class="evidence-link">[e143.1]</a> </li>
    <li>CA1 hippocampal neurons show TIMM underexpression in approximately 27% of subunits (implied from regional comparisons). <a href="../results/extraction-result-143.html#e143.2" class="evidence-link">[e143.2]</a> </li>
    <li>The paper explicitly proposes that 'underexpression of nuclear-encoded ETC subunit genes and reduced expression of mitochondrial translocases (TIMMs/TOMMs) leading to impaired mitochondrial protein import and ETC assembly/function' as mechanism. <a href="../results/extraction-result-143.html#e143.0" class="evidence-link">[e143.0]</a> </li>
    <li>PITRM1 (mitochondrial peptidase) loss in organoids causes proteotoxic stress with increased Aβ and tau, linking mitochondrial proteostasis to AD pathology; rescue with NMN (enhancing mitochondrial NAD+ and clearance) reduces pathology. <a href="../results/extraction-result-25.html#e25.7" class="evidence-link">[e25.7]</a> </li>
</ol>            <h4>Self-Evaluation of Law Novelty (produced by the generation model)</h4>
            <p><strong>Likely Classification:</strong> <span style="color: orange; font-weight: bold;">somewhat-related-to-existing</span></p>
        <p><strong>Explanation:</strong> The region-specific quantification and mechanistic framing as a bottleneck represent a refinement of existing concepts with AD-specific data.</p>            <p><strong>What Already Exists:</strong> Mitochondrial protein import defects have been described in aging and neurodegeneration, and TIMM/TOMM components are known to be required for ETC assembly.</p>            <p><strong>What is Novel:</strong> This statement quantifies region-specific TIMM/TOMM downregulation in AD neurons and explicitly proposes it as a mechanistic bottleneck amplifying ETC dysfunction beyond what would be predicted from ETC subunit gene changes alone.</p>
        <p><strong>References:</strong> <ul>
    <li>Eckert et al. (2010) Mitochondrial dysfunction, apoptotic cell death, and Alzheimer's disease [Mitochondrial dysfunction mechanisms]</li>
    <li>Liang et al. (2008) - source paper [TIMM/TOMM findings in this specific context]</li>
    <li>Pfanner et al. (2019) Mitochondrial proteins: from biogenesis to functional networks [Mitochondrial protein import mechanisms]</li>
</ul>
            <h4>External Evaluations of this Law</h4>
            <p><strong>Predictive Accuracy Evaluation:</strong> <span class="empty-note">Not available.</span></p>
            <p><strong>Novelty Evaluation:</strong> <span class="empty-note">Not available (available only for a randomly selected subset of 100 laws, due to cost).</span></p>
            <hr/>
        </div>
        <div class="section">
            <h2>Theory (Additional Details)</h2>
                        <h3>New Predictions (Likely outcome)</h3>
            <ol>
                <li>Neurons in high-baseline-metabolism regions (association cortex) should show earlier and more severe mitochondrial gene downregulation in preclinical AD (Braak I-II) compared to low-metabolism regions (primary sensory cortex), testable with stage-specific transcriptomics.</li>
                <li>Pharmacological enhancement of mitochondrial biogenesis (e.g., PGC-1α activators, NAD+ precursors like NMN/NR) should preferentially protect neurons in high-metabolism regions (PCC, MTG, CA1) versus low-metabolism regions in AD models.</li>
                <li>Forced expression of TIMM/TOMM translocase components in vulnerable neurons should partially rescue mitochondrial ETC function and improve survival even without correcting ETC subunit gene expression.</li>
                <li>Neurons with experimentally increased metabolic demands (chronic optogenetic stimulation) should show increased vulnerability to AD-related insults (Aβ oligomers, tau) compared to unstimulated neurons.</li>
                <li>Metabolic interventions reducing neuronal activity (e.g., specific inhibitory interneuron activation) should reduce vulnerability of high-activity projection neurons in AD models.</li>
            </ol>
            <h3>New Predictions (Unknown outcome/high-entropy)</h3>
            <ol>
                <li>Whether therapeutic reduction of baseline metabolic demands in vulnerable regions (e.g., through partial activity suppression or metabolic reprogramming to more efficient pathways) would prevent neurodegeneration without causing functional deficits is unknown but could represent a novel therapeutic strategy if energetic demands can be safely lowered.</li>
                <li>Whether selectively boosting mitochondrial function only in projection neuron cell bodies versus along axons and at synaptic terminals would be sufficient for neuroprotection or whether distributed mitochondrial support is required is unknown and critical for therapeutic design.</li>
                <li>Whether the complex I upregulation seen in specific vulnerable subtypes represents an early compensatory phase that later fails, or a maladaptive response from the start, is unclear and would determine whether enhancing or suppressing complex I activity is therapeutic.</li>
                <li>Whether mitochondrial import machinery (TIMM/TOMM) decline is a primary driver of ETC failure or a secondary consequence of broader cellular stress is unresolved and would affect therapeutic targeting priority.</li>
                <li>Whether neurons could be metabolically reprogrammed to rely more on glycolysis and less on oxidative phosphorylation without losing specialized functions is unknown but would test whether OXPHOS dependence is obligatory or flexible.</li>
            </ol>
            <h3>Negative Experiments</h3>
            <ol>
                <li>Finding that regions with high metabolic demands show no greater mitochondrial gene downregulation than low-demand regions would contradict the regional metabolic gradient statement.</li>
                <li>Demonstrating that enhancing mitochondrial function (boosting ETC complex activity, increasing translocase expression) has no effect on neuronal survival in high-metabolism vulnerable populations would challenge the bioenergetic threshold model.</li>
                <li>Showing that neurons with short projections and simple arbors are equally vulnerable as large projection neurons when other variables are controlled would refute the projection length/complexity vulnerability mechanism.</li>
                <li>Finding that mitochondrial import machinery (TIMM/TOMM) expression is normal in vulnerable neurons despite ETC gene downregulation would contradict the import bottleneck mechanism.</li>
                <li>Demonstrating that metabolic interventions reducing neuronal activity have no effect on vulnerability would challenge the demand-supply mismatch model.</li>
            </ol>
            <h3>Unaccounted for Evidence</h3>
<ol>
    <li>The specific molecular signals that cause mitochondrial gene downregulation in vulnerable neurons are not fully explained (upstream transcriptional regulators, signaling pathways). <a href="../results/extraction-result-143.html#e143.0" class="evidence-link">[e143.0]</a> <a href="../results/extraction-result-143.html#e143.1" class="evidence-link">[e143.1]</a> <a href="../results/extraction-result-143.html#e143.2" class="evidence-link">[e143.2]</a> </li>
    <li>Why entorhinal layer II stellate neurons show relatively preserved mitochondrial gene expression (only 23% underexpressed) despite being anatomically highly vulnerable and showing profound cell loss is not fully reconciled. <a href="../results/extraction-result-143.html#e143.3" class="evidence-link">[e143.3]</a> <a href="../results/extraction-result-141.html#e141.0" class="evidence-link">[e141.0]</a> </li>
    <li>The temporal sequence of mitochondrial dysfunction relative to other early molecular changes (synaptic dysfunction, tau pathology, intraneuronal Aβ) is not definitively established. <a href="../results/extraction-result-143.html#e143.0" class="evidence-link">[e143.0]</a> <a href="../results/extraction-result-23.html#e23.0" class="evidence-link">[e23.0]</a> <a href="../results/extraction-result-23.html#e23.2" class="evidence-link">[e23.2]</a> </li>
    <li>Primary motor neuron relative resilience despite long projections suggests additional protective factors beyond what is explained by metabolic demand alone. <a href="../results/extraction-result-23.html#e23.5" class="evidence-link">[e23.5]</a> <a href="../results/extraction-result-23.html#e23.7" class="evidence-link">[e23.7]</a> </li>
</ol>        </div>        <div style="height: 30px;"></div>
    </div>
</body>
</html>